| Literature DB >> 29928653 |
Keir X X Yong1, Ian D McCarthy2, Teresa Poole1,3, Tatsuto Suzuki2, Biao Yang2,4, Amelia M Carton1,5, Catherine Holloway2,6, Nikolaos Papadosifos2, Derrick Boampong2, Julia Langham3, Catherine F Slattery1, Ross W Paterson1, Alexander J M Foulkes1, Jonathan M Schott1, Chris Frost1,3, Nick Tyler2, Sebastian J Crutch1.
Abstract
OBJECTIVE: Deficits in spatial navigation are characteristic and disabling features of typical Alzheimer's disease (tAD) and posterior cortical atrophy (PCA). Visual cues have been proposed to mitigate such deficits; however, there is currently little empirical evidence for their use.Entities:
Year: 2018 PMID: 29928653 PMCID: PMC5989777 DOI: 10.1002/acn3.566
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Figure 1(A) Patient demographic information and background neuropsychological assessment; (B) Composite scores for visual processing domains and SRMT performance. The PCA group was more impaired on composite scores (Wilcoxon rank‐sum: Early: z = −2.32, P = 0.021; Visuoperceptual: z = −2.85, P = 0.004; Visuospatial: z = −2.05, P = 0.041), with weak evidence of greater impairment on the SRMT in the tAD group (z = −1.71, P = 0.088). Visual acuity but not contrast sensitivity was assessed; there was weak evidence for poorer acuity in the PCA than the tAD group (LogMar equivalent: z = 1.73, P = 0.085). Patients are arranged left to right in order of navigational performance from those taking the least to the most time to complete under the baseline (no cues) condition. Impaired scores (performance below 5th%ile) are highlighted in bold font. Mini‐Mental State Examination41; Short Recognition Memory Test42; Concrete synonyms43; Digit span forwards/backwards44; Graded difficulty arithmetic45; Graded difficulty spelling test46; Cortical Visual Screening Test47; Visual Object and Space Perception Battery48; Oblong edge ratio 1:1.2049; Letter Cancellation50; Usual/Unusual Views51; aUnpublished. *Healthy controls do not make errors. SRMT, short recognition memory test; PCA, posterior cortical atrophy; tAD, typical Alzheimer's disease.
Figure 2(A) i – starting position, ii1‐3 – obstacle positions (chosen to interrupt direct path to target destinations), iii1‐3 – target positions, iv – participant position between trials; (B) point defined where participants reached target; (C) right door with obstacle under CCue + motion; arrows indicate direction of motion pattern movement. The setting was constructed at a pedestrian environment laboratory (PAMELA) able to simulate real world environments in a controlled manner.
Summary of data collected, trials censored at the cut‐off time of 60 sec, and medians and interquartile ranges for observed: (A) completion times; (B) proportion of trials where target was fixated; (C) for participants who did fixate, proportion of time where target was fixated during the initial period of trials (FI); (D) walking path SI
| Controls ( | tAD ( | PCA ( | |
|---|---|---|---|
| Data available for both testing blocks (36 trials) | 12 | 9 | 6 |
| Data available for first testing block (18 trials) | 0 | 1 | 2 |
| Completion time | |||
| Participants with trial time data for all 36 trials completed within cut‐off time of 60 sec (%) | 12/12 (100%) | 8/10 (80.0%) | 3/8 (37.5%) |
| Trials completed within cut‐off time of 60 sec/Trials for which data are available (%) | 432/432 (100%) | 333/342 (97.4%) | 224/252 (88.9%) |
|
Completion times (within participant medians) (sec): median (25th%tile, 75th%tile) |
4.40 (3.66, 4.99) |
7.55 (6.26, 10.31) |
8.36 (6.46, 26.53) |
| Fixation measures: whether target was fixated/FI | |||
| Participants with fixation data for all 36 trials (%) | 9/12 (75.0%) | 8/10 (80.0%) | 5/8 (62.5%) |
| Trials with fixation data/Trials for which data are available (%) | 342/432 (79.2%) | 306/342 (89.5%) | 198/252 (78.6%) |
| Number (%) of trials (with fixation data) where target was fixated | 198/342 (57.9%) | 182/306 (59.5%) | 115/198 (58.0%) |
|
% time fixating target (FI) for trials where target was fixated (within participant medians): (median [25th%tile, 75th%tile]) |
19.19 (11.48, 30.61) |
19.51 (8.40, 25.61) |
15.70 (9.94, 19.51) |
| SI | |||
| Participants with SI data for all 36 trials completed within cut‐off time of 60 sec (%) | 7/12 (58.3%) | 7/10 (70.0%) | 3/8 (37.5%) |
| Trials with SI data and completed within cut‐off time of 60 sec/Trials for which data are available (%) | 427/432 (98.8%) | 329/342 (96.2%) | 222/252 (88.1%) |
|
SI (within participant medians): (median [25th%tile, 75th%tile]) |
0.95 (0.95, 0.96) |
0.94 (0.91, 0.95) |
0.93 (0.76, 0.96) |
For the proportion of trials completed within cut‐off time under baseline and cue conditions, see Table S1. FI, fixation index; SI, straightness index; tAD, typical Alzheimer's disease; PCA, posterior cortical atrophy.
Figure 3Graph illustrating selected values of the odds ratio comparing secondary outcome measures between groups and cue conditions. For example, given an estimated odds ratio of 1.2, the figure shows that if the baseline FI or SI is 0.7 then FI or SI with the cue condition is expected to be 0.74, that is the cue condition increases the proportion of initial time spent fixating on the door (for FI) or shortens the path taken by the participant (for SI), compared with baseline. FI, fixation index; SI, straightness index.
Figure 4Walking paths for control, tAD and PCA groups to left, middle and right door without obstacle, under baseline condition (no cues) generated using dead reckoning. Paths were estimated using foot velocity to calculate relative displacement between each step, and so do not show absolute position.27 Data are presented from when participants crossed the starting line. Coloured paths are particularly indirect relative to controls (
Estimated geometric means and percentage reduction in completion time results between cue and baseline conditions for tAD, PCA, combined patient group and controls
| Primary outcome: completion time | ||||||
|---|---|---|---|---|---|---|
| Geometric mean | Percentage reduction in completion time (95% CI) | |||||
| Baseline | CCue | CCue + motion | CCue vs. baseline | CCue + motion vs. baseline | CCue + motion vs. Ccue | |
| tAD | 9.54 | 8.25 | 8.53 | 13.50% (5.18, 21.09) | 10.50% (1.89, 18.35) | −3.47% (−13.4, 5.61) |
| PCA | 12.97 | 11.71 | 12.80 | 9.74% (−9.64, 25.69) | 1.28% (−19.91, 18.73) | −9.37% (−32.8, 9.96) |
| Patients combined | 10.93 | 9.64 | 10.22 | 11.85% (2.54, 20.26) | 6.51% (−3.36, 15.44) | −6.05% (−17.25, 4.08) |
| Controls | 4.16 | 4.16 | 4.18 | −0.13% (−2.14, 1.84) | −0.61% (−2.63, 1.37) | −0.48% (−2.50, 1.49) |
tAD, typical Alzheimer's disease; PCA, posterior cortical atrophy; CCue, Contrast‐cue; CCue + motion, Contrast/Motion‐cue.
Geometric mean is the exponentiated mean of the estimated log transformed completion times.
Estimated comparisons of secondary outcome measures between cue and baseline conditions for tAD, PCA, and combined patient groups. Comparisons are expressed as: (A) odds ratios for whether or not the target was fixated; (B) for the sub‐group of trials where fixation did take place, odds ratios for the proportion of time spent fixating the target (FI); and (C) odds ratios of walking path SI
| Secondary outcomes | ||||||
|---|---|---|---|---|---|---|
| (A) Target fixated | ||||||
| Estimated marginal probability of fixating | Conditional odds ratio (95% CI) | |||||
| Baseline | CCue | CCue + motion | CCue vs. baseline | CCue + motion vs. baseline | CCue + motion vs. Ccue | |
| tAD | 0.52 | 0.56 | 0.68 | 1.22 (0.66, 2.28) | 2.30 (1.21, 4.36) | 1.88 (0.99, 3.56) |
| PCA | 0.50 | 0.63 | 0.63 | 1.91 (0.86, 4.22) | 1.91 (0.86, 4.22) | 1.00 (0.45, 2.22) |
| Patients combined | 0.51 | 0.59 | 0.66 | 1.49 (0.91, 2.44) | 2.11 (1.28, 3.49) | 1.42 (0.86, 2.35) |
| Controls | 0.57 | 0.60 | 0.56 | 1.19 (0.67, 2.13) | 0.96 (0.54, 1.70) | 0.80 (0.45, 1.44) |
tAD, typical Alzheimer's disease; PCA, posterior cortical atrophy; FI, fixation index; SI, straightness index; CCue, Contrast‐cue; CCue + motion, contrast/motion‐cue.
Values for this observed outcome were taken from only the subset of trials where the target was fixated.